

Erratum

TRAIL-mediated armA upregulation enhances the drug resistance of *Klebsiella pneumoniae* by activating the PI3K/AKT/mTOR signaling pathway: Am J Transl Res. 2025; 17(8): 6103-6112

Bu Wang¹, Wei Zhang², Jianhua Liu¹, Hongxia Zhang¹, Maochen Li¹, Xiaocui Peng¹, Zhihua Zhang¹, Ning Song³

¹Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Hebei Northern University, Zhangjiakou, Hebei, P.R. China; ²Department of Microbiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, P.R. China; ³Department of Infectious Diseases, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China

Received December 29, 2025; Accepted May 27, 2026; Epub August 25, 2026; Published August 30, 2026

In this article, we identified some errors in **Figures 1** and **3**. In **Figure 1**, **Figure 1E** should show the statistical graph for IL-6 (pg/mL), and **Figure 1F** should show the statistical graph for IL-1 β (pg/mL). Instead, both **Figure 1E** and **1F** were mistakenly duplicated from **Figure 1D** (TNF- α , pg/mL) in the original **Figure 1**. Hence, we would like to publish this erratum to displace the wrong figures and reflect changes. In **Figure 3**, the fourth graph of **Figure 3D** group name: "OE-TRAIL+si-TRAIL" should be corrected to "OE-TRAIL+si-armA". In addition, the figure legend was missing the description for **Figure 3A**. The following corrected legend should be inserted: "(A) The expression of armA mRNA

was assessed using RT-qPCR". Subsequently, the labels for the remaining panels must be adjusted to (B), (C, D), and (E-G) accordingly. We sincerely apologize for this oversight and any confusion it may have caused. The corrected **Figures 1** and **3** are shown below.

Address correspondence to: Ning Song, Department of Infectious Diseases, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang, Hebei, P.R. China. Tel: +86-15803217260; E-mail: songning_hbmu@126.com

Drug resistance of *Klebsiella pneumoniae*




Figure 1. The drug-resistant *Klebsiella pneumoniae* infection promoted apoptosis and inflammation in A549 cells. A drug-resistant *Klebsiella pneumoniae*-infected A549 cell model was prepared and treated with meropenem. A: Cell viability was quantified using Cell Counting Kit-8 (CCK-8) assay. B, C: Cell apoptosis was examined using flow cytometry. D-F: Tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and interleukin-1 β (IL-1 β) levels were assessed using enzyme-linked immunosorbent assay (ELISA) kits. Data are expressed as mean $\pm$ standard deviation (SD). Ns, no significant; ** $P < 0.01$.

Drug resistance of *Klebsiella pneumoniae*




Figure 3. TRAIL enhanced the drug resistance of *Klebsiella pneumoniae* by upregulating aminoglycoside resistance methylase (*armA*) expression. TRAIL overexpression plasmids (OE-TRAIL) and *armA* siRNA (si-*armA*) were transfected into *Klebsiella pneumoniae*-infected A549 cells and subsequently treated with meropenem. A: The expression of *armA* mRNA was assessed using RT-qPCR. B: Cell viability was quantified using CCK-8 assay. C, D: Cell apoptosis was examined using flow cytometry. E-G: TNF-α, IL-6, and IL-1β levels were assessed using ELISA kits. Data are expressed as mean ± SD. ***P* < 0.01.